Multifactorial seroprofiling dissects the contribution of pre-existing human coronaviruses responses to SARS-CoV-2 immunity.
Multifactorial seroprofiling dissects the contribution of pre-existing human coronaviruses responses to SARS-CoV-2 immunity.
复制标题
DOI：
10.1038/s41467-021-27040-x
复制
发表时间：
2021-11-18
影响因子：
16.6
通讯作者：
Trkola A
中科院分区：
文献类型：
--
作者：
Abela IA;Pasin C;Schwarzmüller M;Epp S;Sickmann ME;Schanz MM;Rusert P;Weber J;Schmutz S;Audigé A;Maliqi L;Hunziker A;Hesselman MC;Niklaus CR;Gottschalk J;Schindler E;Wepf A;Karrer U;Wolfensberger A;Rampini SK;Meyer Sauteur PM;Berger C;Huber M;Böni J;Braun DL;Marconato M;Manz MG;Frey BM;Günthard HF;Kouyos RD;Trkola A
在对循环人类冠状病毒(HCoV)已有免疫的背景下，测定SARS-CoV-2抗体反应对于理解保护性免疫至关重要。在这里，我们使用定制设计的多重ABCORA法对大流行前(N = 825)和感染SARS-CoV-2的捐献者(N = 389)中的SARS-CoV-2和HCoV抗体反应进行了多因素分析。ABCORA血清分析与计算模型相结合，能够准确定义SARS-CoV-2血清转换和预测中和活性，并揭示与HCoV免疫之间有趣的相互关系。具体地说，SARS-CoV-2阴性献血者中较高的HCoV抗体水平表明，先前存在的HCoV免疫可能对SARS-CoV-2感染提供保护。在那些被感染的人中，较高的HCoV活性与SARS-CoV-2反应的升高有关，这表明存在交叉刺激。最重要的是，HCoV免疫可能会影响疾病的严重程度，因为HCoV反应性高的患者不太可能需要住院。综上所述，我们的结果表明，HCoV免疫可能促进SARS-CoV-2特异性免疫的快速发展，从而强调探索交叉保护反应对全面预防冠状病毒的重要性。SARS-CoV-2和人类冠状病毒(HCoV)的串扰是如何诱导免疫反应的，目前尚不清楚。在这里，作者描述了流行前和SARS-CoV-2感染的献血者的体液反应，发现较高的hCoV抗体效价与SARS-CoV-2阴性和SARS-CoV-2阳性患者的住院时间减少有关。
Determination of SARS-CoV-2 antibody responses in the context of pre-existing immunity to circulating human coronavirus (HCoV) is critical for understanding protective immunity. Here we perform a multifactorial analysis of SARS-CoV-2 and HCoV antibody responses in pre-pandemic (N = 825) and SARS-CoV-2-infected donors (N = 389) using a custom-designed multiplex ABCORA assay. ABCORA seroprofiling, when combined with computational modeling, enables accurate definition of SARS-CoV-2 seroconversion and prediction of neutralization activity, and reveals intriguing interrelations with HCoV immunity. Specifically, higher HCoV antibody levels in SARS-CoV-2-negative donors suggest that pre-existing HCoV immunity may provide protection against SARS-CoV-2 acquisition. In those infected, higher HCoV activity is associated with elevated SARS-CoV-2 responses, indicating cross-stimulation. Most importantly, HCoV immunity may impact disease severity, as patients with high HCoV reactivity are less likely to require hospitalization. Collectively, our results suggest that HCoV immunity may promote rapid development of SARS-CoV-2-specific immunity, thereby underscoring the importance of exploring cross-protective responses for comprehensive coronavirus prevention. How the immune responses induced by SARS-CoV-2 and human coronavirus (hCoV) crosstalk is still unclear. Here the authors profile the humoral responses of prepandemic and SARS-CoV-2-infected donors to find that higher hCoV antibody titers are associated with SARS-CoV-2 negativity, and with reduced hospitalization in SARS-CoV-2 positive patients.
登录
查看更多内容
离散的 SARS-CoV-2 抗体滴度与功能性体液稳定性保持一致。
影响因子：
16.6
作者：
Bartsch YC;Fischinger S;Siddiqui SM;Chen Z;Yu J;Gebre M;Atyeo C;Gorman MJ;Zhu AL;Kang J;Burke JS;Slein M;Gluck MJ;Beger S;Hu Y;Rhee J;Petersen E;Mormann B;Aubin MS;Hasdianda MA;Jambaulikar G;Boyer EW;Sabeti PC;Barouch DH;Julg BD;Musk ER;Menon AS;Lauffenburger DA;Nilles EJ;Alter G
通讯作者：
Alter G
影响因子：
5.8
作者：
Gu, Zuguang;Eils, Roland;Schlesner, Matthias
通讯作者：
Schlesner, Matthias
影响因子：
64.8
作者：
Gaebler C;Wang Z;Lorenzi JCC;Muecksch F;Finkin S;Tokuyama M;Cho A;Jankovic M;Schaefer-Babajew D;Oliveira TY;Cipolla M;Viant C;Barnes CO;Bram Y;Breton G;Hägglöf T;Mendoza P;Hurley A;Turroja M;Gordon K;Millard KG;Ramos V;Schmidt F;Weisblum Y;Jha D;Tankelevich M;Martinez-Delgado G;Yee J;Patel R;Dizon J;Unson-O'Brien C;Shimeliovich I;Robbiani DF;Zhao Z;Gazumyan A;Schwartz RE;Hatziioannou T;Bjorkman PJ;Mehandru S;Bieniasz PD;Caskey M;Nussenzweig MC
通讯作者：
Nussenzweig MC
影响因子：
2.2
作者：
Liechti, Thomas;Kadelka, Claus;Trkola, Alexandra
通讯作者：
Trkola, Alexandra
DOI：
10.1016/j.xcrm.2020.100189
发表时间：
2021-01-19
期刊：
Cell reports. Medicine
影响因子：
--
作者：
Ladner JT;Henson SN;Boyle AS;Engelbrektson AL;Fink ZW;Rahee F;D'ambrozio J;Schaecher KE;Stone M;Dong W;Dadwal S;Yu J;Caligiuri MA;Cieplak P;Bjørås M;Fenstad MH;Nordbø SA;Kainov DE;Muranaka N;Chee MS;Shiryaev SA;Altin JA
通讯作者：
Altin JA